Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant association?

Kallweit, U; Baumann, C R; Harzheim, M; Hidalgo, H; Pöhlau, D; Bassetti, C L; Linnebank, M; Valko, P O

Abstract: Background. Fatigue in patients with multiple sclerosis (MS) is highly prevalent and severely impacts quality of life. Recent studies suggested that sleep-disordered breathing (SDB) significantly contributes to fatigue in MS. Study Objective. To evaluate the importance of routine respirography in MS patients with severe fatigue and to explore the effects of treatment with continuous positive airway pressure (CPAP). Patients and Methods. We prospectively assessed the presence of severe fatigue, as defined by a score of 5.0 on the Fatigue Severity Scale (FSS), in 258 consecutive MS patients. Ninety-seven patients (38%) suffered from severe fatigue, whereof 69 underwent overnight respirography. Results. We diagnosed SDB in 28 patients (41%). Male sex was the only independent associate of SDB severity (P = 0.003). CPAP therapy in 6 patients was associated with a significant reduction of FSS scores (5.8 ± 0.5 versus 4.8 ± 0.6, P = 0.04), but the scores remained pathological (≤ 4.0) in all patients. Conclusion. Respirography in MS patients with severe fatigue should be considered in daily medical practice, because SDB frequency is high and CPAP therapy reduces fatigue severity. However, future work is needed to understand the real impact of CPAP therapy on quality of life in this patient group.

DOI: https://doi.org/10.1155/2013/286581
Fatigue and sleep-disordered breathing in multiple sclerosis:
A clinically relevant association?

Ulf Kallweit, MD¹,²; Christian R. Baumann, MD¹;
Michael Harzheim, MD²; Hildegard Hidalgo, MD²; Dieter Pöhlau, MD²;
Claudio L. Bassetti, MD³; Michael Linnebank, MD¹; and Philipp O. Valko, MD¹

¹Department of Neurology, University Hospital Zurich, Zurich, Switzerland;
²Department of Neurology, Kamillus-Klinik, Asbach, Germany;
³Department of Neurology, Inselspital, 3010 Bern, Switzerland.

Running head: Sleep-disordered breathing and fatigue in MS

All authors disclose no financial support or any other conflict of interest.

Corresponding authors:
Ulf Kallweit, MD, Department of Neurology, University Hospital Zurich,
Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
Tel: +41 44 255 55 75, Fax: +41 44 255 46 73, Email: Ulf.Kallweit@usz.ch

Philipp O. Valko, MD, Department of Neurology, University Hospital Zurich,
Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
Tel: +41 44 255 55 11, Fax: +41 44 255 43 80, Email: Philipp.Valko@usz.ch

Character count title: 86
Character count running head: 45
Word count abstract: 237
Word count text body: 3104
Tables: 2
Figures: 2
References: 41
Abstract

**Background:** Fatigue in patients with multiple sclerosis (MS) is highly prevalent and severely impacts quality of life, but current treatment options offer no satisfactory relief. Recent studies suggested that sleep-disordered breathing (SDB) significantly contributes to fatigue in MS.

**Study objective:** To evaluate the importance of routine respirography in MS patients with severe fatigue, and to explore the effects of treatment with continuous positive airway pressure (CPAP).

**Patients and methods:** We prospectively assessed the presence of severe fatigue, as defined by a score of ≥ 5.0 on the Fatigue Severity Scale (FSS), in 258 consecutive MS patients. Ninety-seven patients (38%) suffered from severe fatigue, whereof 69 underwent overnight respirography. We obtained additional information on sleepiness, body mass index, disease severity and duration. Reassessment was done 6 months after installment of CPAP therapy.

**Results:** We diagnosed SDB in 28 patients (41%). Male sex was the only independent associate of SDB severity ($p = 0.003$). CPAP therapy in 6 patients was associated with a significant reduction of FSS scores ($5.8 \pm 0.5$ vs. $4.8 \pm 0.6$, $p = 0.04$), but the scores remained pathological ($\geq 4.0$) in all treated patients.

**Conclusion:** Our findings suggest that respirography in MS patients with severe fatigue should be considered in daily medical practice, because SDB frequency was high and CPAP therapy reduced fatigue severity. Future work is needed to understand the real impact of CPAP therapy on quality of life in this patient group.

**Keywords:** Sleep-disordered breathing; fatigue; multiple sclerosis
Introduction

Although fatigue has been increasingly recognized over the past two decades as one of the most frequent and most debilitating symptoms in patients with MS, there are still no insights into its neurobiological mechanisms, and current treatment options are highly frustrating [1-4]. In clinical practice, MS patients complaining about fatigue are usually first scrutinized for additional and potentially treatable comorbidities, such as depression, pain, anemia or sleep-wake disturbances [5]. If there is no such cause of fatigue, the patient is considered to suffer from “MS-related fatigue”, i.e. a disease-inherent symptom related to the underlying neuroimmunological and neurodegenerative processes, and off-label symptomatic treatment with stimulants of the central nervous system may be recommended [3].

Recently, the need to search for sleep-wake disorders in MS patients has been reemphasized, as several groups observed a significant correlation with fatigue [6-10]. Specifically, sleep-disordered breathing (SDB) has been proposed as a potential risk factor for MS-related fatigue. In the last year, a cross-sectional study in 48 MS patients suggested a predisposition for SDB [11], and two studies found that severe fatigue in MS was significantly associated with SDB and respiratory-related arousals [9,12]. Furthermore, Côté et al. conducted the first controlled, non-randomized clinical treatment study and reported a significant improvement of fatigue following treatment of SDB and other sleep disorders [13]. Very recently, Veauthier et al. were able to identify treatment of sleep disorders in MS patients as independent predictor of fatigue reduction [14].

Taken together, there is increasing amount of data suggesting that SDB should be routinely screened for in all MS patients with severe fatigue. We therefore prospectively assessed the presence and severity of fatigue in consecutive, unselected MS patients seen in a tertiary center and suggested overnight respirography to MS patients with severe fatigue. Patients with SDB were offered CPAP therapy. The main purpose was to elucidate whether routine respirography can be recommended as a screening method in MS patients with severe fatigue, and whether long-term CPAP therapy leads to a clinically meaningful
improvement of fatigue. In addition, we aimed at examining potential predictive factors of SDB in MS patients with fatigue.

Patients and Methods

This prospective study was conducted at the Neurological Department of the Kamillus-Klinik in Asbach, Germany, from October 2010 until March 2011. The study protocol has been reviewed and approved by the local Institutional Review Boards, and all patients gave written informed consent before inclusion.

**Subjects and clinical assessment.** During the above-mentioned period, we prospectively evaluated 258 consecutive patients with multiple sclerosis (MS). The diagnosis of MS was definite in each patient and was made according to standard criteria [15]. The majority of patients suffered from secondary progressive MS (87%) (SPMS), and 13% had a relapsing remitting (RRMS) form. We measured fatigue severity with the Fatigue Severity Scale (FSS), a self-administered questionnaire with nine items that has been validated for various neurological disorders including MS [16,17]. A final score greater than 4.0 is widely accepted to indicate the presence of fatigue. For the purpose of our study, we included only patients with severe fatigue defined by a FSS score ≥ 5.0. The rationale for including only patients with severe fatigue is given by the observation that beneficial treatment effects of CPAP therapy are usually most pronounced in patients with high levels of fatigue [18]. We identified 97 MS patients with severe fatigue. Sixty-nine of them agreed to undergo overnight respirography. We used the Epworth Sleepiness Scale (ESS) to assess sleepiness, with scores ≥ 10 indicating excessive daytime sleepiness (EDS) [19,20]. Information on disease duration was taken from the patients’ medical history. We estimated the severity of disease disability using the Kurtzke’s Expanded Disability Status Scale (EDSS) [21].

**Sleep studies.** Overnight (from 10 p.m. to 6 a.m.) respirography was performed using a portable device (EasyScreen 4.0, Respironixs, Germany), which measured nasal airflow,
pulse rate, arterial oxygen saturation (finger pulse oximetry), and thoracic and abdominal movements. Respirography has been validated previously in patients with ischemic stroke [22]. Apnea was defined by a cessation of nasal airflow ≥10 seconds, and hypopnea by a reduction of nasal airflow by ≥ 50% or ≥ 30%, when associated with an oxygen desaturation ≥ 4% [23]. Apnea-hypopnea index (AHI) was defined by the mean number of apneas and hypopneas per hour. SDB was diagnosed in patients with an AHI ≥ 5/h. SDB was classified as mild (AHI 5-15/h), moderate (AHI 15-30/h), and severe (AHI ≥ 30/h). Apneas were differentiated in obstructive, mixed and central apneas according to standard criteria [23]. Apneas were obstructive if accompanied with continuous respiratory effort, central if unaccompanied by evidence of respiratory effort, and mixed if a central apnea developed respiratory effort with evidence of obstruction later in the apneic interval. A diagnosis of central sleep apnea was made in patients, in whom > 50% of all respiratory events were central. In addition, calculation of the oxygen desaturation-index (ODI) was performed. The magnitude of the oxygen desaturation considered for ODI was ≥ 4%. The analysis was made automatically and corrected visually. Titration of CPAP was performed during overnight video-polysomnography. The optimal therapeutic pressure was determined to eliminate snoring, apneic events with arousals and oxy- hemoglobin desaturations in all body positions and sleep stages. Patients received conventional CPAP therapy (REMstar M series, Philips Respironics® or SOMNOcomfort2, Weinmann®). Reevaluation of FSS and ESS scores was scheduled after a 6-month period of CPAP therapy, although significant short-term relief of both fatigue and sleepiness can be expected already after 3-6 weeks of CPAP therapy [18].

Statistics. Continuous data were expressed as means and standard deviation (SD), categorical variables as numbers and percentage. All analyses were performed with the Statistical Package for the Social Sciences (SPSS, version 17.0). For univariate analysis we used Student’s t-test (for numerical scale variables) and χ²-test (for nominal scale variables). To identify predictors of SDB severity, we performed stepwise multiple linear regression analysis for multivariate analysis, with AHI as dependent variable and the following independent variables: age, sex, disease duration, disease subtype, EDSS, BMI, FSS and
ESS scores. Correlation analyses were performed using the Spearman’s coefficient. Significance was accepted at $p < 0.05$.

**Results**

*Demographic and clinical characteristics.* Sixty-nine MS patients with severe fatigue consented to overnight respirography. The majority was female (70%); mean age was $49.8 \pm 9.2$ years (range: 21-75 years). BMI was $26.0 \pm 4.9$ (range: 17-40). Most patients were severely affected by the disease, as reflected by a mean EDSS of $5.8 \pm 1.4$ (range: 1.0-8.5) and mean disease duration of $13.7 \pm 8.8$ years (range: 1-33 years). The patient group that declined respirography ($n = 28$) showed similar demographic and clinical characteristics (data not shown).

*Sleep-disordered breathing.* Overnight respirography revealed a mean AHI of $9.3 \pm 16.9$/h and a mean ODI of $10.5 \pm 14.7\%$. SDB was found in 28 MS patients (41%), and was mild in 18 patients (26%), moderate in 3 patients (4%), and severe in 7 patients (10%). SDB was obstructive in all but one patient. MS patients with SDB were significantly older ($p = 0.01$), and tended to be more often male ($p = 0.06$). Likewise, AHI correlated with age ($\rho = 0.33$, $p = 0.006$), but not with EDSS, disease duration or BMI. Table 1 provides the remaining demographic and clinical characteristics (table 1).

*Excessive daytime sleepiness.* The overall prevalence of excessive daytime sleepiness in our patient group was high (51%). The presence of excessive daytime sleepiness, however, was similar between patients with and without SDB (61% vs. 44%, $p = 0.13$). Even when comparing patients with moderate-severe SDB and those without SDB, we did not detect any differences in the prevalence of SDB (70% vs. 44%, $p = 0.30$). Similarly, there was no correlation between ESS scores and AHI ($r = -0.05$, $p = 0.66$).

*Sex-related differences.* The gender ratio ($f : m$) was $3.6 : 1$ in patients without SDB, but the male proportion significantly increased with more severe SDB ($p = 0.005$): the ratio
was 2.6 : 1 in mild SDB, 0.5 : 1 in moderate SDB, and 0.4 : 1 in severe SDB. BMI was similar in both male and female patients (25.3 ± 3.8 vs. 26.3 ± 5.2, p = 0.12), but AHI was significantly higher in male patients (18.5 ± 24.7 vs. 5.2 ± 9.9, p < 0.001). Multiple regression analysis confirmed that male sex was an independent associate of SDB severity (p = 0.003). Figure 1 shows the different relative distribution of SDB in male and female patients. Otherwise, the clinical characteristics were similar in both sex groups (table 2).

*Evolution of FSS and ESS under CPAP therapy.* We recommended CPAP therapy to all patients with an AHI ≥ 10/h (n = 14). Nine patients agreed, but 3 of them did not tolerate the device. The remaining 6 patients (2 with RRMS, 4 with SPMS) revealed a CPAP daily average adherence of ≥ 5 hours per night during the 6-month treatment. In these patients, AHI decreased during CPAP therapy from 39.2 ± 26.3/h to 5.2 ± 3.6/h (p = 0.02), and the minimal SaO₂ improved from 71.5 ± 11.7% to 88.2 ± 1.9% (p = 0.02). EDSS remained stable (6.3 ± 1.3 vs. 6.3 ± 1.2). At follow-up after 6 months, CPAP therapy was associated with a significant decrease of FSS scores (5.8 ± 0.5 vs. 4.8 ± 0.6, p = 0.04), whereas ESS scores did not change (9.8 ± 3.5 vs. 9.5 ± 3.0, p = 0.61) (Figure 2). However, despite the significant reduction of fatigue severity during CPAP therapy, FSS scores remained pathologic (≥ 4.0) in all treated patients.

**Discussion**

Considering the increasing interest in SDB as a potential risk factor for fatigue in MS, the primary goal of this prospective investigation – so far the largest respirography study on SDB in MS – was to understand, whether routine overnight respirography should be done in all MS patients with severe fatigue. We found a SDB frequency of 41% among MS patients with severe fatigue and demonstrated that CPAP therapy was associated with a significant improvement of fatigue severity, while sleepiness remained unchanged. Furthermore, only male sex could be identified as independent predictor of SDB in MS patients with severe
fatigue. Taken together, these findings indicate that routine respirography should be considered in this specific patient group, but future work is needed to confirm our results and establish the exact benefit of SDB treatment also in terms of quality of life.

Although the observed SDB frequency was rather high, our study was not designed to estimate the prevalence of SDB in MS or to compare its prevalence between MS patients with and without fatigue, as we did not perform respirography in MS patients with FSS scores < 5.0 and did not include a control group. Moreover, comparison to other studies is hampered by disparities of included patient cohorts, methodological and technical differences, and by heterogeneous definitions of SDB. In this line, two recent studies on SDB and fatigue in MS differed with regard to the applied polysomnographic scoring criteria, one group used the Rechtschaffen and Kales criteria and the other study scored according to the 1999 American Academy of Sleep Medicine Task Force [9,12,24]. The two methods use different placement of EEG electrodes, which may affect the scoring of respiratory arousals. Thus, several reasons may account for the large discrepancy of reported prevalence of SDB in MS patients with or without fatigue. For instance, two earlier studies did not find any cases with SDB, as defined by an AHI ≥ 5/h, among 37 and 10 MS patients, respectively, although the majority of these patients suffered from fatigue [25,26]. On the other hand, Kaminska et al. performed polysomnography in 37 MS patients with severe fatigue, as defined by the same criteria as in our study, and found severe SDB (AHI > 30/h) in 32%, relative to 8% among 25 MS patients without severe fatigue [12]. Using another fatigue questionnaire, Veauthier et al. reported a SDB prevalence of 27% and 2.5% in 26 MS patients with fatigue and 40 MS patients without fatigue, respectively [9]. Finally, Braley et al. reported a mean AHI of 17.0 ± 18.8/h in 48 MS patients, a much higher number than in our study [11]. Overall, these studies illustrate our uncertainty regarding prevalence and severity of SDB in MS and its relationship to fatigue.

Six MS patients with SDB and severe fatigue showed significant reduction of fatigue severity after 6 months of CPAP therapy: FSS scores decreased from 5.8 ± 0.5 to 4.8 ± 0.6. In other words, long-term CPAP therapy resulted in a 17% fatigue reduction. Our results are
in line with the recent study of Côté et al., who treated 17 MS patients with SDB and fatigue, reporting a decrease of FSS scores from 5.0 ± 1.7 to 4.3 ± 1.7, corresponding to a 13% amelioration [13]. In addition, the reduction of mean FSS scores in both studies was > 0.6, which has been suggested by Putzki et al. as “clinical significant” improvement [27]. On the other hand, however, the final FSS score was still above 4.0, which is a widely accepted cut-off for fatigue [17]. Considering the high burden of MS-related fatigue, any alleviation would certainly be desirable, even if only marginal. However, by now we do not really know, to what extent the observed reductions of the FSS score represent a benefit to affected patients, especially in terms of quality of life. Worthy of mention, a multivariate analysis in the study of Côté et al. failed to detect any improvement of quality of life after CPAP therapy, as examined by the Physical and Mental Component Summary scale of the Short Form (36) Health Survey (SF-36) [13]. The number of studies on health-related quality of life in MS patients is very large, and fatigue has been identified as an independent predictor [28-30]. Thus, the lack of improvement in quality of life challenges the significance of CPAP therapy in MS-related fatigue. A possible explanation could be that the level of depression, which is an ever stronger predictor of quality of life in MS, did not improve during CPAP therapy, thereby obscuring a potential benefit [28-30].

Additional considerations highlight the ambiguous relationship between fatigue and SDB in MS patients. First, we currently lack any objective tool that enables us to quantify fatigue. Thus, rating of treatment outcomes regarding fatigue relies solely on subjective estimation. Second, and closely related to the first point, a possible placebo effect cannot be ruled out. As evidenced by a recent randomized, double-blind controlled trial, the placebo effect of sham CPAP therapy may be quite considerable: ESS scores decreased in the placebo group from 15.2 ± 4.0 to 11.9 ± 5.9 (p = 0.001), corresponding to an effect size of 0.82, but results of the Osler test did not change [31]. Furthermore, the placebo group showed also a significant improvement of several items of the SF-36 [31]. Other groups confirmed this substantial placebo effect of CPAP therapy on sleepiness and quality of life [32]. A few groups studied fatigue response to CPAP therapy in SDB patients without
underlying neurological disease, generating similar results [33-35]. While most groups uniformly reported a significant improvement of fatigue during CPAP therapy, the findings from 2 double-blind, randomized controlled trials observed significant reductions of fatigue scores also during placebo CPAP therapy [34,35]. Recently, Tomfohr et al. confirmed that long-term CPAP therapy leads to a benefit on fatigue beyond placebo effects [18]. In summary, these studies clearly illustrate the importance of a randomized, placebo controlled trial in order to demonstrate that the observed improvement of fatigue in MS after CPAP therapy is more than a mere placebo effect.

An intriguing finding of our study is the lack of correlation between sleepiness and SDB. Other groups made similar observations in MS patients, regarding both subjective and objective measures of sleepiness [12,36]. In general, sleepiness is regarded as the main daytime consequence of SDB, caused by repeated apnea-induced arousals, sleep fragmentation and reduced slow-wave sleep, and a marked reduction of sleepiness has been demonstrated following CPAP therapy [37]. The high prevalence of sleepiness in our cohort and its persistence under CPAP therapy suggest that SDB is not the main etiology of sleepiness in MS patients with fatigue. The prevalence of most sleep-wake disturbances in MS has been shown to be increased in MS compared to the general population, and may thus account for the observed high prevalence of sleepiness [7]. On the other hand, sleepiness and fatigue in MS – generally regarded as two distinct symptoms – may share a common pathophysiology. The observation that the correlation between FSS and ESS scores in MS is much stronger than in subjects with various sleep disorders, is also supportive of this hypothesis [38,39].

Finally, our study demonstrates that sleepiness, BMI or disease severity are not useful predictors of SDB in MS patients with severe fatigue. Conversely, male and elder MS patients are more likely to present moderate-severe SDB. This illustrates that the presence of SDB among MS patients with severe fatigue may clinically not appear as obvious as it is in subjects with "classical" SDB.
We have to acknowledge several limitations. First of all, the number of treated patients was small, making general conclusions difficult. Second, we did not assess possible confounders such as mood disorders, and did not measure the effects of CPAP therapy on quality of life. Third, we did not include a control group. Furthermore, the additional presence of other sleep-wake disturbances has not been assessed. The prevalence of most sleep disorders is increased in MS patients [7], and effective improvement of fatigue in MS patients may require tailored therapies of more than only one sleep disorder [13,14]. In particular, a recent meta-analysis indicated that restless-legs syndrome is frequent in MS, with reported prevalences of 12-58%, and restless legs syndrome appears to be associated with fatigue in MS [40]. Finally, future studies should prefer polysomnography instead of respirography, as the latter does not allow detecting apnea-induced EEG arousals, and they might use additional fatigue scales such as the Modified Fatigue Impact Scale (MFIS), which has been shown to assess cognitive and psychosocial functioning more accurately than the FSS [41]. Nevertheless, we believe that our study provides an additional piece of clinical experience to the current discussion on the role of SDB in MS patients with fatigue.

In conclusion, our study confirms that SDB and fatigue are associated features in MS, and that SDB treatment leads to a small yet statistically significant reduction of fatigue. However, well-designed studies are needed to substantiate the clinical relevance of this association, by proving that fatigue reduction following CPAP therapy has a meaningful impact on quality of life that goes beyond a mere placebo effect.

Acknowledgements

The EasyScreen was sponsored by Heinen+Löwenstein, Medizintechnik, Bad Ems, Germany.
References

1. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45:435–7.

2. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21:9-14.

3. Brañas P, Jordan R, Fry-Smith A, Burla A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4:1-61.

4. Stankoff B, Waubant E, Vonfaverux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. J Neurol 2005; 64:1139-43.

5. Tachibana N, Howard RS, Hirsch NP, Miller DH, Moseley IF and Fish D. Sleep problems in multiple sclerosis. Eur Neurol 1994; 34: 320–3.

6. Atarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004; 61:525-8.

7. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 2010; 14:121-9.

8. Mills RJ, Young CA. The relationship between fatigue and other clinical features of multiple sclerosis. Mult Scler 2011; 604-12.

9. Veauthier C, Radbruch H, Gaede G, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler 2011; 17:613-22.

10. Kaminska M, Kimoff RJ, Schwartzman K, Trojan DA. Sleep disorders and fatigue in multiple sclerosis: Evidence for association and interaction. J Neurol Sci 2011; 302:7-13.

11. Braley TJ, Segal BM, Chervin RD. Sleep-disordered breathing in multiple sclerosis. Neurology 2012; 79:929-36.
12. Kaminska M, Kimoff RJ, Benedetti A, et al. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler 2012; 18:1159-69.

13. Côté I, Trojan DA, Kaminska M, et al. Impact of sleep disorder treatment on fatigue in multiple sclerosis. Mult Scler 2013; 19:480-9.

14. Veauthier C, Gaede G, Radbruch, Gottschalk S, Wernecke KD, Paul F. Treatment of sleep disorders may improve fatigue in multiple sclerosis. Clin Neurol Neurosurg 2013 (in press).

15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria". Ann Neurol 2005; 58: 840-6.

16. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121-3.

17. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31:1601-7.

18. Tomfohr LM, Ancoli-Israel S, Loredo JS, Dimsdale JE. Effects of continuous positive airway pressure on fatigue and sleepiness in patients with obstructive sleep apnea: data from a randomized controlled trial. Sleep 2011; 34:121-6.

19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-5.

20. Bloch KE, Schoch OD, Zhang JN, Russi EW. German version of the Epworth sleepiness scale. Respiration 1999; 66:440-7.

21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-52.
22. Selic C, Siccoli MM, Hermann DM, Bassetti CL. Blood pressure evolution after acute ischemic stroke in patients with and without sleep apnea. Stroke 2005; 36:2614-8.

23. Iber C, Ancoli-Israel S, Chesson A, Quan SF for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, first Ed.: Westchester, Illinois: American Academy of Sleep Medicine, 2007.

24. Veauthier C, Blau A, Paul F. ‘Obstructive sleep apnea is associated with fatigue in multiple sclerosis’ by Kaminska et al. Mult Scler 2013;19:372-3.

25. Wunderlin BW, Kesselring J, Ginzler H, et al. Fatigue in multiple sclerosis is not due to sleep apnea. Eur J Neurol 1997; 4:72-8.

26. Kaynak H, Altintas A, Kaynak D, et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol 2006; 13:1333-9.

27. Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur Neurol 2008; 59:136-42.

28. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000; 6:181-5.

29. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. J Neurol Sci 2002; 205:51-8.

30. Mitchell AJ, Benito-León J, Morales González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4:556-66.

31. Siccoli MM, Pepperell JCT, Kohler M, Craig SE, Davies RJO, Stradling JR. Effects of continuous positive airway pressure on quality of life in patients with moderate to severe obstructive sleep apnea: data from a randomized controlled trial. Sleep 2008; 31:1551-8.
32. Montserrat JM, Ferrer M, Hernandez L, et al. Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome. Am J Respir Crit Care Med 2001; 164:608-13.

33. Chotinaiwattarakul W, O’Brien LM, Fan L, Chervin RD. Fatigue, tiredness, and lack of energy improve with treatment for OSA. J Clin Sleep Med 2009; 5:240-5.

34. Haensel A, Norman D, Natarajan L, Bardwell WA, Ancoli-Israel S,Dimsdale JE. Effect of a 2 week CPAP treatment of mood states in patients with obstructive sleep apnea: a double-blind trial. Sleep Breath 2007; 11:239-44.

35. Yu BH, Ancoli-Israel S, Dimsdale JE. Effect of CPAP treatment on mood states in patients with sleep apnea. J Psychiatr Res 1999; 33:427-32.

36. Neau JP, Paquereau J, Auche V. Sleep disorders and multiple sclerosis: a clinical and polysomnography study. Eur Neurol 2012; 68:8-15.

37. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airway pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev (Online) 2006.

38. Merkelbach S, Schulz H. What have fatigue and sleepiness in common? J Sleep Res 2006; 15:105-6.

39. Hossain JL, Ahmad P, Reinish LW, et al. Subjective fatigue and subjective sleepiness: two independent consequences of sleep disorders? J Sleep Res 2005; 14:245-53.

40. Schürks M, Bussfeld P. Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis. Eur J Neurol 2013; 20:605-15.

41. Téllez N, Río J, Tintoré M, Nos C, Galán I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005; 11:198-202.
Table 1  Demographic and clinical characteristics in severely fatigued MS patients with and without sleep-disordered breathing.

|                         | no SDB (AHI < 5/h) | SDB (AHI ≥ 5/h) | p   |
|-------------------------|--------------------|-----------------|-----|
| n (%)                   | 41 (59%)           | 28 (41%)        |     |
| Female sex, n (%)       | 32 (78%)           | 16 (57%)        | 0.06|
| Age [y]                 | 47.4 ± 8.3         | 53.3 ± 9.5      | 0.01|
| BMI                     | 25.4 ± 5.2         | 26.8 ± 4.2      | 0.27|
| Disease duration [y]    | 13.8 ± 8.9         | 13.6 ± 8.8      | 0.92|
| Disease subtype         |                    |                 | 0.73|
| RRMS                    | 3                  | 6               |     |
| SPMS                    | 25                 | 35              |     |
| EDSS                    | 5.9 ± 1.5          | 5.8 ± 1.3       | 0.79|
| FSS                     | 5.7 ± 0.7          | 5.5 ± 0.9       | 0.36|
| ESS                     | 9.4 ± 4.7          | 9.7 ± 3.8       | 0.79|
| EDS (ESS ≥ 10)          | 18 (44%)           | 17 (61%)        | 0.13|

BMI: Body-Mass-Index [kg/m²]
EDS: Excessive Daytime Sleepiness
EDSS: Expanded Disability Status Scale
ESS: Epworth Sleepiness Scale
FSS: Fatigue Severity Scale
RRMS: Relapsing-Remitting Multiple Sclerosis
SPMS: Secondary Progressive Multiple Sclerosis
Table 2  Gender-related differences in MS patients with severe fatigue.

|                                | Female          | Male           | p     |
|--------------------------------|-----------------|----------------|-------|
| n (%)                          | 48 (70%)        | 21 (30%)       |       |
| Age [y]                        | 49 ± 9.3        | 51 ± 9.2       | 0.73  |
| Disease duration [y]           | 14.4 ± 9.1      | 11.9 ± 7.7     | 0.16  |
| Disease subtype                |                 |                | 0.71  |
| RRMS                           | 7               | 2              |       |
| SPMS                           | 41              | 19             |       |
| EDSS                           | 5.9 ± 1.4       | 5.8 ± 1.4      | 0.78  |
| ESS                            | 9.7 ± 4.5       | 9.2 ± 3.8      | 0.65  |
| EDS (ESS ≥ 10)                 | 25 (52%)        | 10 (48%)       | 0.49  |
| BMI                            | 26.3 ± 5.2      | 25.3 ± 3.8     | 0.12  |
| No SDB (AHI < 5/h)             | 32 (67%)        | 9 (43%)        | 0.06  |
| AHI                            | 5.2 ± 9.9       | 18.5 ± 24.7    | <0.001|
| ODI                            | 7.1 ± 7.9       | 18.1 ± 22.4    | <0.001|
| SaO₂ min [%]                   | 78.9 ± 14.6     | 75.5 ± 19.1    | 0.58  |

AHI: Apnea-Hypopnea Index  
BMI: Body Mass Index  
EDS: Excessive daytime sleepiness  
EDSS: Extended Disability Status Scale  
ESS: Epworth Sleepiness Scale  
ODI: Oxygen-Desaturation Index  
RRMS: Relapsing-Remitting Multiple Sclerosis  
SaO₂ min: Minimal O₂ saturation  
SDB: Sleep-disordered breathing  
SPMS: Secondary Progressive Multiple Sclerosis
Male MS patients with severe fatigue were more frequently affected by SDB than female MS patients with severe fatigue.
Follow-up under long-term treatment with continuous positive air pressure (CPAP) reveals significant reduction of FSS scores but not of ESS scores.

FSS: Fatigue Severity Scale
ESS: Epworth Sleepiness Scale